Post-discharge pharmacotherapy in people with atrial fibrillation hospitalized for acute myocardial infarction: an Australian cohort study 2018–22

Author:

Deakin Claire T1ORCID,Costa Juliana de Oliveira1ORCID,Brieger David23ORCID,Lin Jialing1ORCID,Schaffer Andrea L4ORCID,Kidd Michael5ORCID,Pearson Sallie-Anne1ORCID,Falster Michael O1ORCID

Affiliation:

1. Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 , Australia

2. Department of Cardiology, Concord Repatriation General Hospital , Sydney 2139 , Australia

3. Faculty of Medicine and Health, University of Sydney , Sydney 2006 , Australia

4. Nuffield Department of Primary Care Health Sciences, Bennett Institute for Applied Data Science, University of Oxford , Oxford OX2 6GG , UK

5. Centre for Future Health Systems, Faculty of Medicine and Health, UNSW Sydney , Sydney 2052 , Australia

Abstract

Abstract Background Dual antiplatelet therapy with P2Y12 inhibitors (P2Y12i) and aspirin following acute myocardial infarction (AMI) prevents future ischaemic events. People with atrial fibrillation (AF) also require oral anticoagulants (OAC), increasing bleeding risk. Guidelines recommend post-discharge prescribing of direct OAC with clopidogrel and discontinuation of P2Y12i after 12 months, but little is known about use in clinical practice. Aim To describe post-discharge use of OACs and P2Y12i in people with AF and a history of OAC use hospitalized for AMI. Methods and results We identified 1330 people hospitalized for AMI with a diagnosis of AF and history of OAC use in New South Wales, Australia, July 2018–June 2020. We identified three aspects of post-discharge antithrombotic medicine use with possible safety implications: (1) not being dispensed OACs; (2) dispensing OAC and P2Y12i combinations associated with increased bleeding (involving warfarin, ticagrelor, or prasugrel); and (3) P2Y12i use longer than 12 months. After discharge, 74.3% of people were dispensed an OAC, 45.4% were dispensed a P2Y12i, and 35.8% were dispensed both. People with comorbid heart failure or cancer were less likely to receive OACs. Only 11.2% of people who dispensed both an OAC and P2Y12i received combinations associated with increased bleeding; this was more common among people with chronic kidney disease or prior warfarin or statin use. A total of 44.6% of people dispensed both medicines continued P2Y12i for over 12 months; this was more common in people who received a revascularization or lived in areas of social disadvantage. Conclusion We identified potential gaps in pharmacotherapy, including underuse of recommended therapies at discharge, use of combinations associated with increased bleeding, and P2Y12i use beyond 12 months. Prescribing vigilance across both hospital and community care is required.

Funder

National Health and Medical Research Council

Heart Foundation

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3